Advances in gut microbiota-related treatment strategies for managing colorectal cancer in humans  

作　　者：Bhaskar Roy Kunfeng Cao Chabungbam Orville Singh Xiaodong Fang Huanming Yang Dong Wei 

机构地区：[1]Hangzhou Institute of Medicine(HIM),Chinese Academy of Science,Hangzhou 310022,China [2]BGI Research,Shenzhen 518083,China [3]College of Life Sciences,University of Chinese Academy of Sciences,Beijing 100049,China [4]College of Animal Sciences,Zhejiang University(Zijingang Campus),Hangzhou 310058,China [5]James D.Watson Institute of Genome Sciences,Hangzhou 310029,China [6]Clin Lab,BGI Genomics,Beijing 100000,China

出　　处：《Cancer Biology & Medicine》2025年第2期93-112,共20页癌症生物学与医学(英文版)

基　　金：the Hangzhou Institute of Medicine(HIM)and Chinese Academy of Sciences for supporting work of this article。

摘　　要：Colorectal cancer(CRC)is a major contributor to global cancer-related mortality with increasing incidence rates in both developed and developing regions.Therefore,CRC presents a significant challenge to global health.The development of innovative tools for enhancing early CRC screening and diagnosis,along with novel treatments and therapies for improved management,remains an urgent necessity.CRC is intricately associated with the gut microbiota,which is integral to food digestion,nutrient generation,drug metabolism,metabolite production,immune enhancement,endocrine regulation,neurogenesis modulation,and the maintenance of physiologic and psychological equilibrium.Dysbiosis or imbalances in the gut microbiome have been implicated in various disorders,including CRC.Emerging evidence highlights the critical role of the gut microbiome in CRC pathogenesis and treatment,which presents potential opportunities for early detection and diagnosis.Despite substantial advances in understanding the relationship between the gut microbiota and CRC,significant challenges persist.Gaining a deeper and more detailed understanding of the interactions between the human microbiota and cancer is essential to fully realize the potential of the microbiota in cancer management.Unlike genetic factors,the gut microbiome is subject to modification,offering a promising avenue for the development of CRC treatments and drug discovery.This review provides an overview of the interactions between the human gut microbiome and CRC,while examining prospects for precision management of CRC.

关 键 词：Gut microbiome colorectal cancer microbial biomarkers precision medicine 

分 类 号：R73[医药卫生—肿瘤]